ロード中...
Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?
Many studies have shown evidence that erythropoiesis-stimulating agents (ESAs), as a classic treatment for chronic kidney disease (CKD)-related anemia, have several disadvantages and may trigger various adverse events with long-term use. The hypoxia-induced factor (HIF) pathway has been intensively...
保存先:
| 出版年: | Front Med (Lausanne) |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5786558/ https://ncbi.nlm.nih.gov/pubmed/29404328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2017.00259 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|